Key result
Chemotherapeutic drugs, including anthracyclines, immune checkpoint inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, and 5-fluorouracil, are associated with an increased risk of coronary atherosclerosis and adverse cardiovascular events.
Why the study?
Chemotherapy-induced coronary heart disease impairs prognosis in cancer patients, and new discoveries regarding drug effects and mechanisms on coronary artery disease require summarization to guide prevention and treatment strategies.
Do chemotherapeutic drugs increase the risk of coronary atherosclerosis and adverse cardiovascular events in patients with tumors?
Do chemotherapeutic drugs increase the risk of coronary atherosclerosis and adverse cardiovascular events in patients with tumors?
This review highlights the significant risk of coronary atherosclerosis and cardiovascular adverse events associated with various chemotherapeutic agents, emphasizing the need for cardiovascular risk management during cancer treatment.
May prompt closer CV monitoring during chemotherapy; hypothesis-generating pending prospective trials.
Cardiovascular disease, particularly coronary artery disease, is the leading cause of death in humans worldwide. Coronary heart disease caused by chemotherapy affects the prognosis and survival of patients with tumors. The most effective chemotherapeutic drugs for cancer include proteasome inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, 5-fluorouracil, and anthracyclines. Animal models and clinical trials have consistently shown that chemotherapy is closely associated with coronary events and can cause serious adverse cardiovascular events. Adverse cardiovascular events after chemotherapy can affect the clinical outcome, treatment, and prognosis of patients with tumors. In recent years, with the development of new chemotherapeutic drugs, new discoveries have been made about the effects of drugs used for chemotherapy on cardiovascular disease and its related mechanisms, such as inflammation. This review article summarizes the effects of chemotherapeutic drugs on coronary artery disease and its related mechanisms to guide efforts in reducing cardiovascular adverse events during tumor chemotherapy, preventing the development of coronary heart disease, and designing new prevention and treatment strategies for cardiotoxicity caused by clinical tumor chemotherapy.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2023) conducted a review in Cancer and Coronary Atherosclerosis. Chemotherapeutic drugs (anthracyclines, immune checkpoint inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, 5-fluorouracil) was evaluated. Chemotherapeutic drugs, including anthracyclines, immune checkpoint inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, and 5-fluorouracil, are associated with an increased risk of coronary atherosclerosis and adverse cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: